Overcoming 5-Fu Resistance of Colon Cells through Inhibition of Glut1 by the Specific Inhibitor WZB117

  • Liu, Wei (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
  • Fang, Yong (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
  • Wang, Xiao-Tong (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
  • Liu, Ju (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University) ;
  • Dan, Xing (Northeast Pharmaceutical Group Sales Co., Ltd.) ;
  • Sun, Lu-Lu (Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University)
  • Published : 2014.09.15


Background: 5-Fluorouracil (5-FU) is the most commonly used drug in colon cancer therapy. However, despite impressive clinical responses initially, development of drug resistance to 5-Fu in human tumor cells is the primary cause of failure of chemotherapy. In this study, we established a 5-Fu-resistant human colon cancer cell line for comparative chemosensitivity studies. Materials and Methods: Real time PCR and Western blotting were used to determine gene expression levels. Cell viability was measured by MTT assay. Glucose uptake was assess using an Amplex Red Glucose/Glucose Oxidase assay kit. Results: We found that 5-Fu resistance was associated with the overexpression of Glut1 in colon cancer cells. 5-Fu treatment at low toxic concentration induced Glut1 expression. At the same time, upregulation of Glut1 was detected in 5-Fu resistant cells when compared with their parental cells. Importantly, inhibition of Glut1 by a specific inhibitor, WZB117, significantly increased the sensitivity of 5-Fu resistant cells to the drug. Conclusions: This study provides novel information for the future development of targeted therapies for the treatment of chemo-resistant colon cancer patients. In particular it demonstrated that Glut1 inhibitors such as WZB117 may be considered an additional treatment options for patients with 5-Fu resistant colon cancers.


  1. Carvalho KC, Cunha IW, Rocha RM, et al (2011). GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics, 66, 965-72.
  2. Beck A, Etienne MC, Cheradame S, et al (1994). A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer, 30, 1517-22.
  3. Boyer J, McLean EG, Aroori S, et al (2004). Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res, 10, 2158-67.
  4. Curtin NJ, Harris AL, Aherne GW (1991). Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res, 51, 2346-52.
  5. DeBraud F, Munzone E, Nole F, et al (1998). Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol, 21, 279-83.
  6. Herrmann R (1996). 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol, 7, 551-2.
  7. Hur H, Xuan Y, Kim YB, et al (2013). Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol, 42, 44-54.
  8. Li LJ, Li GD, Wei HL, et al (2014). Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells. Asian Pac J Cancer Prev, 15, 3123-8.
  9. Liu Y, Cao Y, Zhang W, et al (2012). A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther, 11, 1672-82.
  10. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330-8.
  11. Peters GJ, van Triest B, Backus HH, et al (2000). Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer, 36, 916-24.
  12. Subbarayan PR, Lee K, Ardalan B (2010). Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. Anticancer Res, 30, 1157-62.
  13. Vander HM, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33.
  14. Wang FS, Aschele C, Sobrero A, et al (1993). Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res, 53, 3677-80.
  15. Wang YD, Li SJ, Liao JX (2013). Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat, 12, 525-35.
  16. Wood TE, Dalili S, Simpson CD, et al (2008). A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther, 7, 3546-55.
  17. Wu CH, Ho YS, Tsai CY, et al (2009). In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int J Cancer, 124, 2210-9.
  18. Zhang N, Yin Y, Xu SJ, et al (2008). 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 13, 1551-69.
  19. Zhao Y, Butler EB, Tan M (2013). Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis, 4, 532.
  20. Zhao Y, Liu H, Liu Z, et al (2011). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res, 71, 4585-97.
  21. Zhao L, Wang WJ, Zhang JN, et al (2014). 5-Fluorouracil and Interleukin-2 immunochemotherapy enhances immunogenicity of Non-Small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44.

Cited by

  1. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity vol.37, pp.2, 2016,
  2. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation vol.77, pp.5, 2016,
  3. gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma vol.12, pp.10, 2017,
  4. Brucine Sensitizes HepG2 Human Liver Cancer Cells to 5-fluorouracil via Fas/FasL Apoptotic Pathway vol.13, pp.3, 2017,
  5. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells vol.8, pp.2, 2017,
  6. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy vol.234, pp.1, 2018,
  7. Role of metabolism in cancer cell radioresistance and radiosensitization methods vol.37, pp.1, 2018,